Semaglutide
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 572
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Treatment group A: HRS9531 injection | n/r | n/r | n/r | n/r | n/r |
| Treatment group B: Semaglutide Injection | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.